- Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (P
Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis
Watch Aldeyra Therapeutics' latest callAldeyra Therapeutics (NASDAQ:ALDX) Q2 2025 Earnings Call · Replay · May 6, 2025Read the transcript of Aldeyra Therapeutics (NASDAQ:ALDX) Q2 2025 Earnings CallAldeyra Therapeutics, Inc. on 6ix
In the deck
Story so far
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
- Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
- Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
Earlier from Aldeyra Therapeutics
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
- Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
- Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
- Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
- Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
Later from Aldeyra Therapeutics
- Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
- Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
- Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
Follow Aldeyra Therapeutics into a list and get an email when it puts out news.
Follow Aldeyra Therapeutics